Clinical Trial Update: Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating switching to Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) to improve tolerability and adherence in people with HI…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide)

Snippet

Sponsor: Midland Research Group, Inc. | Conditions: Human Immunodeficiency Virus | Phase 4 | Status: TERMINATED